227 related articles for article (PubMed ID: 22137560)
21. XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers.
Yeh KT; Wu YH; Lee MC; Wang L; Li CT; Chen CY; Lee H
Ann Surg Oncol; 2012 Mar; 19(3):734-42. PubMed ID: 21861227
[TBL] [Abstract][Full Text] [Related]
22. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
23. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
24. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
27. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Nishimura M; Ueda N; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Feb; 13(2):217-22. PubMed ID: 15643501
[TBL] [Abstract][Full Text] [Related]
29. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
30. Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC.
Luo YQ; Ming Z; Zhao L; Yao LJ; Dong H; Du JP; Wu SZ; Hu W
IUBMB Life; 2012 May; 64(5):423-31. PubMed ID: 22473740
[TBL] [Abstract][Full Text] [Related]
31. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer.
Liu H; Zhang T; Ye J; Li H; Huang J; Li X; Wu B; Huang X; Hou J
Cancer Immunol Immunother; 2012 Oct; 61(10):1849-56. PubMed ID: 22456757
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
[TBL] [Abstract][Full Text] [Related]
35. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
36. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
Friboulet L; Barrios-Gonzales D; Commo F; Olaussen KA; Vagner S; Adam J; Goubar A; Dorvault N; Lazar V; Job B; Besse B; Validire P; Girard P; Lacroix L; Hasmats J; Dufour F; André F; Soria JC
Clin Cancer Res; 2011 Sep; 17(17):5562-72. PubMed ID: 21750204
[TBL] [Abstract][Full Text] [Related]
37. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
[TBL] [Abstract][Full Text] [Related]
38. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
[TBL] [Abstract][Full Text] [Related]
39. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
40. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]